Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889512 · ClinicalTrials.gov registry record · Phase 4
The Luveris In Vitro Fertilization Trial
A Phase 4 study, sponsored by University Reproductive Associates.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00889512: Clinical Trial Phase 4 study, sponsored by University Reproductive Associates.
NCT00889512 is a Phase 4 study that was terminated before completion, run by University Reproductive Associates. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00889512, a Phase 4 study, was terminated before completion, sponsored by University Reproductive Associates.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a new protocol using two different types of fertility drugs that is more similar to the way the hormones act in a normal menstrual cycle (period). We are recruiting women who are trying to get pregnant through In Vitro Fertilization (IVF) who either have a high prolactin level (a hormone normally found in your blood that is produced in the brain) or have a condition known as hypothalamic amenorrhea in which one does not get regular periods due to low hormone levels. The ovaries can be stimulated with Follicle Stimulating Hormone (FSH) alone and with FSH and Luteinizing Hormone (LH). FSH causes eggs to be made while LH causes estrogen (hormone) production. The women in this study have low hormone levels and need both FSH and LH. Luveris® (LH hormone) is a new drug approved for egg production and is used in IVF. There is no set amount of LH nor a set protocol for LH use. Therefore, we are testing this new regimen. One group of women will receive a fixed dose of LH throughout their cycle while the other will decrease the dose of FSH while at the same time increasing the LH dose which is what happens in the natural menstrual cycle.
Interventions
- DRUG Luveris fixed dose
- DRUG Luveris increasing dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Why NCT00889512 stopped before completion
NCT00889512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Luveris fixed dose is the first listed.
NCT00889512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00889512 about?
NCT00889512 is a clinical study titled "The Luveris In Vitro Fertilization Trial". The purpose of this study is to develop a new protocol using two different types of fertility drugs that is more similar to the way the hormones act in a normal menstrual cycle (period). We are recruiting women who are trying to get pregnant through In Vitro Fertilization (IVF) who either have a hi...
What is the current status of trial NCT00889512?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2009-04. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00889512?
The interventions under investigation include: Luveris fixed dose (DRUG), Luveris increasing dose (DRUG).
Who is sponsoring clinical trial NCT00889512?
This trial is sponsored by University Reproductive Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00889512's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia